

SEMINARS IN THROMBOSIS AND HEMOSTASIS – VOLUME 14 INDEX

AUTHOR INDEX

- | | | | |
|----------------------------------|-----------------------------|------------------------------|---------------------|
| Andrew M, 28 | Dol F, 18 | Hirsh J, 116 | Samama MM, 293, 363 |
| Austin M, 137 | Dupouy D, 18 | Hoak JC, 202 | Scanu AM, 266 |
| Aviram M, 258 | Edwards EH, 189 | Hornstra G, 59 | Schaefer EJ, 143 |
| Badimon JJ, 50 | Edwards RL, 88 | Juhan-Vague I, 180 | Schmidt B, 28 |
| Badimon L, 50 | Eskin SG, 170 | Kelley JL, 189 | Schonfeld G, 184 |
| Bastida E, 66 | Esmon CT, 210 | Leaf A, 290 | Schwartz CJ, 189 |
| Berliner JA, 206 | Esmon NL, 210 | Levine MN, 116 | Sie P, 18 |
| Bick RL, 133, 222, 293, 299, 363 | Feinstein DI, 351 | Lisiewicz J, 339 | Sprague EA, 189 |
| Black PL, 79 | Fenton JW, 234 | Loskutoff DJ, 100 | Spector AA, 196 |
| Boneu B, 18 | Fogelman AM, 206 | McIntire LV, 170 | Talmadge JE, 79 |
| Booyse FM, 175 | Fuster V, 50 | McNamara JR, 143 | Territo M, 206 |
| Bradley WA, 165, 175, 253 | Gabaig AM, 18 | Mitropoulos KA, 246 | Thomas DP, 1 |
| Brook JG, 258 | Genest Jr. J, 149 | Murano G, 133, 222, 293, 363 | Tracy PB, 227 |
| Bruce R, 175 | Gianturco SH, 165, 175, 253 | Navab M, 206 | Turpie AGG, 41 |
| Buchanan MR, 33 | Goodnight Jr. SH, 285 | Ofosu FA, 9 | Valente AJ, 189 |
| Cadroy Y, 18 | Gray E, 9 | Ordovs JM, 143 | Van Lenten BJ, 206 |
| Caranobe C, 18 | Grossman BA, 241 | Owen J, 241 | Vega GL, 149 |
| Chesbro J, 50 | Grundey SM, 149 | Palmer RH, 241 | Walker FJ, 216 |
| Collen D, 95, 180 | Gurewich V, 110 | Rickles FR, 88, 126 | Wenzel E, 293, 363 |
| Connor WE, 271 | Hancock WW, 88, 126 | | Zacharski LR, 88 |
| D'Amore PA, 73 | | | |

CUMULATIVE TABLE OF CONTENTS

- Number 1**
THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC, AND FIBRINOLYTIC DRUGS: A MECHANIC POINT OF VIEW
 Eva Bastida, Ph.D., Michael R. Buchanan, Ph.D., and Frederick A. Ofosu, Ph.D.
- Overview of Venous Thrombogenesis**, Duncan P. Thomas, 1
- Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties**, Frederick A. Ofosu and Elaine Gray, 9
- Pharmacokinetic Studies of Standard Unfractionated Heparin and Low Molecular Weight Heparins in the Rabbit**, Bernard Boneu, Claudine Caranobe, Yves Cadroy, Frederique Dol, Anne-Marie Gabaig, Dominique Dupouy, and Pierre Sie, 18
- Use of Heparin in Newborn Infants**, Maureen Andrew and Barbara Schmidt, 28
- Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds**, Michael R. Buchanan, 33
- Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism**, Alexander G. G. Turpie, 41
- Prevention of Thromboembolism Induced by Prosthetic Heart Valves**, Valentin Fuster, Lina Badimon, Juan J. Badimon, and James Chesebro, 50
- Effect of Dietary Lipids on Arterial Thrombus Formation: Rationale for the Support of Drug Therapy by Diet**, Gerard Hornstra, 59
- The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis**, Eva Bastida, 66
- Antiangiogenesis as a Strategy for Antimetastasis**, Patricia A. D'Amore, 73
- Immunotherapy of Metastatic Disease**, James E. Talmadge and Paul L. Black, 79
- Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulant and/or Antiplatelet Drugs in Cancer Treatment**, Frederick R. Rickles, Wayne W. Hancock, Richard L. Edwards, and Leo R. Zacharski, 88
- Potential Approaches for Therapeutic Intervention of Thrombosis by Fibrinolytic Agents**, Desire Collen, 95
- Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy**, David J. Loskutoff, 100
- Pro-Urokinase: Physicochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of Action**, Victor Gurewich, 110
- Clinical Use of Low Molecular Weight Heparins and Heparinoids**, Mark N. Levine and Jack Hirsh, 116
- Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions**, Frederick R. Rickles and Wayne W. Hancock, 126
- Abstracts of Current Literature**, Genesis Murano and Rodger L. Bick, 133

SEMINARS IN THROMBOSIS AND HEMOSTASIS – VOLUME 14 INDEX

AUTHOR INDEX

- | | | | |
|----------------------------------|-----------------------------|------------------------------|---------------------|
| Andrew M, 28 | Dol F, 18 | Hirsh J, 116 | Samama MM, 293, 363 |
| Austin M, 137 | Dupouy D, 18 | Hoak JC, 202 | Scanu AM, 266 |
| Aviram M, 258 | Edwards EH, 189 | Hornstra G, 59 | Schaefer EJ, 143 |
| Badimon JJ, 50 | Edwards RL, 88 | Juhan-Vague I, 180 | Schmidt B, 28 |
| Badimon L, 50 | Eskin SG, 170 | Kelley JL, 189 | Schonfeld G, 184 |
| Bastida E, 66 | Esmon CT, 210 | Leaf A, 290 | Schwartz CJ, 189 |
| Berliner JA, 206 | Esmon NL, 210 | Levine MN, 116 | Sie P, 18 |
| Bick RL, 133, 222, 293, 299, 363 | Feinstein DI, 351 | Lisiewicz J, 339 | Sprague EA, 189 |
| Black PL, 79 | Fenton JW, 234 | Loskutoff DJ, 100 | Spector AA, 196 |
| Boneu B, 18 | Fogelman AM, 206 | McIntire LV, 170 | Talmadge JE, 79 |
| Booyse FM, 175 | Fuster V, 50 | McNamara JR, 143 | Territo M, 206 |
| Bradley WA, 165, 175, 253 | Gabaig AM, 18 | Mitropoulos KA, 246 | Thomas DP, 1 |
| Brook JG, 258 | Genest Jr. J, 149 | Murano G, 133, 222, 293, 363 | Tracy PB, 227 |
| Bruce R, 175 | Gianturco SH, 165, 175, 253 | Navab M, 206 | Turpie AGG, 41 |
| Buchanan MR, 33 | Goodnight Jr. SH, 285 | Ofosu FA, 9 | Valente AJ, 189 |
| Cadroy Y, 18 | Gray E, 9 | Ordovs JM, 143 | Van Lenten BJ, 206 |
| Caranobe C, 18 | Grossman BA, 241 | Owen J, 241 | Vega GL, 149 |
| Chesbro J, 50 | Grundy SM, 149 | Palmer RH, 241 | Walker FJ, 216 |
| Collen D, 95, 180 | Gurewich V, 110 | Rickles FR, 88, 126 | Wenzel E, 293, 363 |
| Connor WE, 271 | Hancock WW, 88, 126 | | Zacharski LR, 88 |

CUMULATIVE TABLE OF CONTENTS

- Number 1**
THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC, AND FIBRINOLYTIC DRUGS: A MECHANIC POINT OF VIEW
 Eva Bastida, Ph.D., Michael R. Buchanan, Ph.D., and Frederick A. Ofosu, Ph.D.
- Overview of Venous Thrombogenesis**, Duncan P. Thomas, 1
- Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties**, Frederick A. Ofosu and Elaine Gray, 9
- Pharmacokinetic Studies of Standard Unfractionated Heparin and Low Molecular Weight Heparins in the Rabbit**, Bernard Boneu, Claudine Caranobe, Yves Cadroy, Frederique Dol, Anne-Marie Gabaig, Dominique Dupouy, and Pierre Sie, 18
- Use of Heparin in Newborn Infants**, Maureen Andrew and Barbara Schmidt, 28
- Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds**, Michael R. Buchanan, 33
- Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism**, Alexander G. G. Turpie, 41
- Prevention of Thromboembolism Induced by Prosthetic Heart Valves**, Valentin Fuster, Lina Badimon, Juan J. Badimon, and James Chesebro, 50
- Effect of Dietary Lipids on Arterial Thrombus Formation: Rationale for the Support of Drug Therapy by Diet**, Gerard Hornstra, 59
- The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis**, Eva Bastida, 66
- Antiangiogenesis as a Strategy for Antimetastasis**, Patricia A. D'Amore, 73
- Immunotherapy of Metastatic Disease**, James E. Talmadge and Paul L. Black, 79
- Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulant and/or Antiplatelet Drugs in Cancer Treatment**, Frederick R. Rickles, Wayne W. Hancock, Richard L. Edwards, and Leo R. Zacharski, 88
- Potential Approaches for Therapeutic Intervention of Thrombosis by Fibrinolytic Agents**, Desire Collen, 95
- Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy**, David J. Loskutoff, 100
- Pro-Urokinase: Physicochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of Action**, Victor Gurewich, 110
- Clinical Use of Low Molecular Weight Heparins and Heparinoids**, Mark N. Levine and Jack Hirsh, 116
- Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions**, Frederick R. Rickles and Wayne W. Hancock, 126
- Abstracts of Current Literature**, Genesis Murano and Rodger L. Bick, 133

Number 2

**HYPERTRIGLYCERIDEMIA, ARTERIOSCLEROSIS,
AND THROMBOSIS: I**

Sandra H. Gianturco, Ph.D. and Momtaz K. Wassef, Ph.D.

Epidemiologic Associations Between Hypertriglyceridemia and Coronary Heart Disease, Melissa Austin, 137**Clinical Significance of Hypertriglyceridemia**, Ernst J. Schaefer, Judith R. McNamara, Jacques Genest, Jr., and Jose M. Ordovas, 143**Hypertriglyceridemia: Causes and Relation to Coronary Heart Disease**, Scott M. Grundy and Gloria Lena Vega, 149**Lipoprotein-Mediated Cellular Mechanisms for Atherogenesis in Hypertriglyceridemia**, Sandra H. Gianturco and William A. Bradley, 165**Hemodynamic Effects on Atherosclerosis and Thrombosis**, Suzanne G. Eskin and Larry V. McIntire, 170**Normal but Not Hypertriglyceridemic Very Low-Density Lipoprotein Induces Rapid Release of Tissue Plasminogen Activator from Cultured Human Umbilical Vein Endothelial Cells**, F. M. Booyse, R. Bruce, S. H. Gianturco, and W. A. Bradley, 175**Fibrinolysis and Atherosclerosis**, D. Collen and I. Juhan-Vague, 180
Hypertriglyceridemia in Noninsulin Dependent Diabetes Mellitus, Gustav Schonfeld, 184**Thrombosis and the Development of Atherosclerosis: Rokitsansky Revisited**, Colin J. Schwartz, Anthony J. Valente, Jim L. Kelley, Eugene A. Sprague, and Ellen H. Edwards, 189**Lipid and Lipoprotein Effects on Endothelial Eicosanoid Formation**, Arthur A. Spector, 196**Platelets and Atherosclerosis**, John C. Hoak, 202**Lipoprotein Receptors and Endothelial Cells**, Alan M. Fogelman, Judith A. Berliner, Brian J. Van Lenten, Mahamad Navab, and Mary Territo, 206**Protein C and the Endothelium**, Naomi L. Esmon and Charles T. Esmon, 210**Interactions of Protein S With Membranes**, Frederick J. Walker, 216**Abstracts of Current Literature**, Genesio Murano and Rodger L. Bick, 222

Number 3

**HYPERTRIGLYCERIDEMIA, ARTERIOSCLEROSIS,
AND THROMBOSIS: II**

Sandra H. Gianturco, Ph.D. and Momtaz K. Wassef, Ph.D.

Regulation of Thrombin Generation at Cell Surfaces, Paula B. Tracy, 227**Regulation of Thrombin Generation and Functions**, John W. Fenton II, 234**Hyperlipidemia and in vivo Hemostatic System Activation**, John Owen, Betty A. Grossman, and Robert H. Palmer, 241**Hypercoagulability and Factor VII in Hypertriglyceridemia**, K. A. Mitropoulos, 246**Vitamin K-Dependent Proteins Bind to Very Low-Density Lipoproteins**, William A. Bradley and Sandra H. Gianturco, 253**Platelet Lipoprotein Interactions**, J. Gerald Brook and M. Aviram, 258**Lipoprotein(a): A Genetically Determined Lipoprotein Containing a Glycoprotein of the Plasminogen Family**, Angelo M. Scanu, 266**Effects of Omega-3 Fatty Acids in Hypertriglyceridemic States**, William E. Connor, 271**Effects of Dietary Fish Oil and Omega-3 Fatty Acids on Platelets and Blood Vessels**, Scott H. Goodnight, Jr., 285**Effects of n-3 Fatty Acids on Reocclusion After Angioplasty**, Alexander Leaf, 290**Abstracts of Current Literature**, Rodger L. Bick, Genesio Murano, Meyer M. Samama, and Ernst Wenzel, 293

Number 4

DISSEMINATED INTRAVASCULAR COAGULATION: I

Rodger L. Bick, M.D., F.A.C.P.

Disseminated Intravascular Coagulation and Related Syndromes, Rodger L. Bick, 299**Disseminated Intravascular Coagulation in Acute Leukemia**, Jerzy Lisiewicz, 339**Treatment of Disseminated Intravascular Coagulation**, Donald I. Feinstein, 351**Abstracts of Current Literature**, Rodger L. Bick, Genesio Murano, Meyer M. Samama, and Ernst Wenzel, 363